AstraZeneca: results for lung cancer drug Tagrisso

(CercleFinance.com) - The Anglo-Swedish pharmaceutical group has announced that Tagrisso has demonstrated unprecedented disease-free survival in the adjuvant treatment of stage IB-IIIA patients with EGFR-mutated lung cancer.


The Phase III ADAURA trial showed that treatment with Tagrisso after curative surgery reduced the risk of disease recurrence or death by 80%.

Over two years, 89% of patients in the trial treated with Tagrisso remained alive and free of disease compared to 53% under placebo.

The results will be presented during the plenary session of the American Society of Clinical Oncology ASCO20 Virtual Scientific Program on 31 May.



Copyright (c) 2020 CercleFinance.com. All rights reserved.